Memantine
Market, by Formulation (Tablet and Capsule), by Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by
Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and
Africa) -Size, Share, Outlook, and Opportunity Analysis 2018 – 2026
Memantine is a non-acetyl
cholinesterase inhibitor drug that aids in treatment of Alzheimer's disease.
The drug received European marketing approval in 2002 and the U.S. Food and
Drug Administration (U.S FDA) approval in 2003. The generic versions of the
drugs are available since 2015. Memantine aids in treatment of moderate to
severe dementia associated with Alzheimer's disease. However the drug may show
a severe skin reaction called Stevens-Johnson syndrome (associated with painful
blisters on the skin) after prolonged use.
Memantine Market– Drivers
Increasing number of pipeline
studies for use of memantine are expected to boost growth of the memantine
market. For instance, in September 2016, Lille University Hospital started
phase I clinical study for assessing the effects of memantine on cognitive
behavior of patients associated with Alzheimer’s disease. The study is estimated
to be completed by February 2019.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2255
Furthermore, Suven Life Sciences
Limited is undergoing phase II clinical study for the comparative study on
safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for
treating moderate Alzheimer’s disease. The study was started in September 2015
and is expected to be completed in May 2019.
Memantine Market– Restraint
Increasing number of expired
patents of drugs is a major factor hindering growth of the global memantine
market. For instance, according Merz Pharmaceuticals, a Germany-based company,
in October 2018, overall licensing income during patented period for memantine
decreased due to expiration of patent protection in a majority of markets. For
instance, according to Merz Pharmaceuticals, the U.S. licensing income for
memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34
million in year 2016.
Memantine Market– Regional
Analysis
On the basis of region, the
global memantine market is segmented into North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/memantine-market-2255
North America is expected to hold
dominant position in the global memantine market, owing to increasing number of
generic versions of memantine in the U.S. market. For instance, in February
2018, Lupin Limited announced the launch of its Memantine Hydrochloride
Extended-Release Capsules in the U.S. market. The capsules are available in
7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the
U.S. FDA. These are indicated for the treatment of moderate to severe dementia
of the Alzheimer’s disease.
Furthermore, Asia Pacific is
expected to witness significant growth in the global memantine market, owing to
increasing focus of key players in manufacturing memantine tablets. For
instance, in October 2018, Dr. Reddy’s Laboratories launched memantine
hydrochloride tablets in the Indian market. They are available in 5mg and 10mg,
equivalent to generic version of Namenda tablets, which were already available
in the U.S. market in July 2015.
Memantine Market– Competitive
Analysis
Key players operating in the
global memantine market include, Merz Pharmaceuticals, Lupin Limited, Allergan
plc. Novartis AG, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd.,
Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories, and Johnson &
Johnson Services, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2255
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment